Five commonly used traditional Chinese medicine formulas in the treatment of ulcerative colitis: A network meta-analysis

BACKGROUND Currently, traditional Chinese medicine (TCM) formulas are commonly being used as adjunctive therapy for ulcerative colitis in China. Network meta-analysis, a quantitative and comprehensive analytical method, can systematically compare the effects of different adjunctive treatment options for ulcerative colitis, providing scientific evidence for clinical decision-making. AIM To evaluate the clinical efficacy and safety of commonly used TCM for the treatment of ulcerative colitis (UC) in clinical practice through a network meta-analysis. METHODS Clinical randomized controlled trials of these TCM formulas used for the adjuvant treatment of UC were searched from the establishment of the databases to July 1, 2022. Studies that met the inclusion criteria were screened and evaluated for literature quality and risk of bias according to the Cochrane 5.1 standard. The methodological quality of the studies was assessed using ReviewManager (RevMan) 5.4, and a funnel plot was constructed to test for publication bias. ADDIS 1.16 statistical software was used to perform statistical analysis of the treatment measures and derive the network relationship and ranking diagrams of the various intervention measures. RESULTS A total of 64 randomized controlled trials involving 5456 patients with UC were included in this study. The adjuvant treatment of UC using five TCM formulations was able to improve the clinical outcome of the patients. Adjuvant treatment with Baitouweng decoction (BTWT) showed a significant effect mean difference = 36.22, 95% confidence interval (CI): 7.63, 65.76. For the reduction of tumor necrosis factor in patients with UC, adjunctive therapy with BTWT (mean difference = −9.55, 95%CI: −17.89, −1.41), Shenlingbaizhu powder SLBZS; odds ratio (OR) = 0.19, 95%CI: 0.08, 0.39, and Shaoyao decoction (OR = −23.02, 95%CI: −33.64, −13.14) was effective. Shaoyao decoction was more effective than BTWT (OR = 0.12, 95%CI: 0.03, 0.39), SLBZS (OR = 0.19, 95%CI: 0.08, 0. 39), and Xi Lei powder (OR = 0.34, 95%CI: 0.13, 0.81) in reducing tumor necrosis factor and the recurrence rate of UC. CONCLUSION TCM combined with mesalazine is more effective than mesalazine alone in the treatment of UC.